Side-by-side · Research reference

CardiogenvsN-Acetyl Epitalon Amidate

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BAnimal-StrongHUMAN-REVIEWED12/45 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

N-Acetyl Epitalon Amidate

Bioregulator Tetrapeptide · Khavinson School

10 passagesExtra divisionsKhavinson 2004

Telomerase+Enzyme inductionKhavinson 2003

4-AATetrapeptide

SQ · Variable protocols

01Mechanism of Action

Parameter

Cardiogen

N-Acetyl Epitalon Amidate

Primary target

Cardiovascular cell gene expressionKhavinson 2022

DNA promoter regions (telomerase, RNA polymerase II, retinal genes)

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003 Khavinson 2004

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

—

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

N-Acetyl Epitalon Amidate

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

No standardized human dosing in indexed literature

In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

Not specified in candidate papers

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

In vitro human cell cultureKhavinson 2004 Khavinson 2003

Route

Subcutaneous injection

—

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

Chronic treatment in aging culture

Sustained effect through late passages.

Cell culture protocol

—

Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004

Cells made 10 extra divisions (44 passages total vs 34 in control).

Modification stability

—

N-acetyl + C-amide caps enhance peptidase resistance

Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.

04Side Effects & Safety

Parameter

Cardiogen

N-Acetyl Epitalon Amidate

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Human safety data

—

Not available in indexed literature

Candidate papers describe in vitro and animal models only.

Theoretical telomerase risk

—

Telomerase activation in somatic cells raises theoretical oncogenic transformation concern

In vitro observations

—

No cytotoxicity reported in human fetal fibroblast cultureKhavinson 2004

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

N-Acetyl Epitalon Amidate

·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

N-Acetyl Epitalon Amidate

·Individuals with hereditary cancer syndromes or high genetic cancer risk

05Administration Protocol

Parameter

Cardiogen

N-Acetyl Epitalon Amidate

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.

3. Timing

Variable — often evening injection. No established circadian preference.

Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

—

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

N-Acetyl Epitalon Amidate

+ Thymalin

Moderate

View Thymalin →

Both are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.

Epitalon: Protocol not defined in indexed literature
Thymalin: Tissue-specific bioregulator · separate dosing
Rationale: Complementary transcriptional targets
Primary benefit: Dual-axis aging intervention: cellular senescence + immune restoration